FDA Approves Jelmyto (mitomycin) for Treatment of Low-Grade Upper Tract Urothelial Cancer

Article Link: FDA Approves Jelmyto (mitomycin) for Treatment of Low-Grade Upper Tract Urothelial Cancer

PRINCETON, N.J.–(BUSINESS WIRE)–Apr. 15, 2020– UroGen Pharma Ltd. (Nasdaq: URGN) today announced the U.S. Food and Drug Administration (FDA) granted expedited approval for Jelmyto (mitomycin) for pyelocalyceal solution, a first-in-class treatment…

Source: FDA New Drug Approvals